Clinical Trial Update: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating GI-4000 with bevacizumab and either FOLFOX or FOLFIRI in colon cancer; the study was terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX
• GI-4000

Snippet

Sponsor: Georgetown University | Conditions: Colon Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-08-15